T cell activity after dendritic cell vaccination is dependent on both the type of antigen and the mode of delivery

Journal of Immunology

Volumn 164, Issue 9, 2000, Pages 4961-4967

  Serody, Jonathan S ^a,b   Collins, Edward J ^b   Tisch, Roland M ^b   Kuhns, Jennifer J ^b   Frelinger, Jeffrey A ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ARTICLE; CELL ACTIVITY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTO ONCOGENE; T LYMPHOCYTE; VACCINATION;

EID: 0034193987     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.9.4961     Document Type: Article

References (47)

1. Tsai, V., I. Kawashima, E. Keogh, K. Daly, A. Sette, and E. Celis. 1998. In vitro immunization and expansion of antigen-specific cytotoxic T lymphocytes for adoptive immunotherapy using peptide-pulsed dendritic cells. Crit. Rev. Immunol. 18:65.
2. Tsai, V., S. Southwood, J. Sidney, K. Sakaguchi, Y. Kawakami, E. Appella, A. Sette, and E. Celis. 1997. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J. Immunol. 158:1796.
3. Tjoa, B. A., S. J. Erickson, V. A. Bowes, H. Ragde, O. M. Kenny, O. E. Cobb, R. C. Ireton, M. J. Troychak, A. L. Boynton, and G. P. Murphy. 1997. Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate 32:272.
4. Tjoa, B., A. Boynton, G. Kenny, H. Ragde, S. L. Misrock, and G. Murphy. 1996. Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. Prostate 28:65.
5. Thurnher, M., H. Klocker, C. Papesh, R. Ramoner, C. Radmayr, A. Hobisch, G. Gastl, N. Romani, S. Ebner, G. Bock, et al. 1997. Dendritic cells for the immunotherapy of renal cell carcinoma. Urol. Int. 59:1.
6. Schuler, G., and R. M. Steinman. 1997. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J. Exp. Med. 186:1183.
7. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nut. Med. 4:321.
8. Ollila, D. W., M. C. Kelley, G. Gammon, and D. L. Morton. 1998. Overview of melanoma vaccines: active specific immunotherapy for melanoma patients. Semin. Surg. Oncol. 14:328.
9. Lotze, M. T. 1997. Getting to the source: dendritic cells as therapeutic reagents for the treatment of patients with cancer Ann. Surg. 226:1.
10. Lotze, M. T., M. Shurin, I. Davis, A. Amoscato, and W. J. Storkus. 1997. Dendritic cell based therapy of cancer. Adv. Exp. Med. Biol. 417:551.
11. Greenberg, P. D., J. P. Klarnet, D. E. Kern, and M. A. Cheever. 1988. Therapy of disseminated tumors by adoptive transfer of specifically immune T cells. Prog. Exp. Tumor Res. 32:104.
12. Boon, T., P. Coulie, M. Marchand, P. Weynants, T. Wolfel, and V. Brichard. 1994. Genes coding for tumor rejection antigens: perspectives for specific immunotherapy. Important Adv. Oncol. 1:53.
13. Akbari, O., N. Panjwani, S. Garcia, R. Tascon, D. Lowrie, and B. Stockinger. 1999. DNA vaccination: transfection and activation of dendritic cells as key events for immunity. J. Exp. Med. 189:169.
14. Bystryn, J. C. 1998. Vaccines for melanoma: design strategies and clinical results. Dermatol. Clin. 16:269.
15. Murphy, G. P., B. A. Tjoa, S. J. Simmons, J. Jarisch, V. A. Bowes, H. Ragde, M. Rogers, A. Elgamal, G. M. Kenny, O. E. Cobb, et al. 1999. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 38:73.
16. Mutis, T., R. Verdijk, E. Schrama, B. Esendam, A. Brand, and E. Goulmy. 1999. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood 93:2336.
17. Bijilmakers, M., and H. Ploegh. 1993. Putting together an MHC class I molecule. Curr. Opin. Immunol. 5:21.
18. Bjorkman, P. J., M. A. Saper, B. Samraoui, W. S. Bennett, J. L. Strominger, and D. C. Wiley. 1987. Structure of the human class I histocompatibility antigen. HLA-A2. Nature 329:506.
19. Maffei, A., K. Papadopoulos, and P. E. Harris. 1997. MHC class I antigen processing pathways. Hum. Immunol. 54:91.
20. Parker, K. C., M. Shields, M. DiBrino, A. Brooks, and J. E. Coligan. 1995. Peptide binding to MHC class I molecules: implications for antigenic peptide prediction. Immunol. Res. 14:34.
21. Parker, K. C., M. A. Bednarek, and J. E. Coligan. 1994. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 152:163.
22. Parham, P. 1995. Antigen presentation by class 1 major histocompatibility complex molecules: a context for thinking about HLA-G. Am. J. Reprod. Immunol. 34:10.
23. Baselga, J., D. Tripathy, J. Mendelsohn, S. Baughman, C. C. Benz, L. Dantis, N. T. Sklarin, A. D. Seidman, C. A. Hudis, J. Moore, et al. 1996. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14:737.
24. Baselga, J., A. D. Seidman, P. P. Rosen, and L. Norton. 1997. HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology 11:43.
25. Linehan, D. C., P. S. Goedegebuure, G. E. Peoples, S. O. Rogers, and T. J. Eberlein. 1995. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. J. Immunol. 155: 4486.
26. Navabi, H., B. Jasani, M. Adams, A. S. Evans, M. Mason, T. Crosby, and L. Borysiewicz. 1997. Generation of in vitro autologous human cytotoxic T-cell response to E7 and HER-2/neu oncogene products using ex-vivo peptide loaded dendritic cells. Adv. Exp. Med. Biol. 417:583.
27. Salter, R. D., and P. Cresswell. 1986. Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid. EMBO J. 5:943.
28. Matsui, M., R. J. Moots, R. J. Warburton, A. L. Peace-Brewer, L. G. Tussey, D. G. Quinn, A. J. McMichael, and J. A. Frelinger. 1995. Genetic evidence for difference between intracellular and extracellular peptides in influenza A matrix peptide-specific CTL recognition. J. Immunol. 154:1088.
29. + chronic myelogenous leukemia-specific allogeneic T lymphocytes. Cancer Res. 57:1547.
30. + progenitors in serum-free medium. Adv. Exp. Med. Biol. 417:161.
31. Collins, E. J., D. N. Garboczi, M. N. Karpusas, and D. C. Wiley. 1995. The three-dimensional structure of a class I major histocompatibility complex molecule missing the α3 domain of the heavy chain. Proc. Natl. Acad. Sci. USA 92:1218.
32. Gorga, J. C., A. Dong, M. C. Manning, R. W. Woody, W. S. Caughey, and J. L. Strominger. 1989. Comparison of the secondary structures of human class I and class II major histocompatihility complex antigens by Fourier transform infrared and circular dichroism spectroscopy. Proc. Natl. Acad. Sci. USA 86:2321.
33. Pogue, R. R., J. Eron, J. A. Frelinger, and M. Matsui. 1995. Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity. Proc. Natl. Acad. Sci. USA 92:8166.
34. Fahnestock, M. L., I. Tamir, L. Narhi, and P. J. Bjorkman. 1992. Thermal stability comparison of purified empty and peptide-filled forms of a class I MHC molecule. Science 258:1658.
35. Eggert, A. A., M. W. Schreurs, O. C. Boerman, W. J. Oyen, A. J. de Boer, C. G. Figdor, and G. J. Adema. 1999. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res. 59:3340.
36. Parkhurst, M. R., M. L. Salgaller, S. Southwood, P. F. Robbins, A. Sette, S. A. Rosenberg, and Y. Kawakami, 1996. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol. 157:2539.
37. Lustgarten, J., M. Theobald, C. Labadie, D. LaFace, P. Peterson, M. L. Disis, M. A. Cheever, and L. A. Sherman. 1997. Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD8. Hum. Immunol. 52:109.
38. Wentworth, P. A., A. Vitiello, J. Sidney, E. Keogh, R. W. Chesnut, H. Grey, and A. Sette. 1996. Differences and similarities in the A2.1-restricted cylotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice. Eur. J. Immunol. 26:97.
39. Morse, M. A., R. E. Coleman, G. Akabani, N. Niehaus, D. Coleman, and H. K. Lyerly. 1999. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res. 59:56.
40. Chan, V. W., S. Kothakota, M. C. Rohan, L. Pangamban-Lustan, J. P. Gardner, M. S. Wachowicz, J. A. Winter, and L. T. Williams. 1999. Secondary lymphoid-tissue chemokine (SLC) is chemotactic for mature dendritic cells. Blood 93:3610.
41. Gunn, M. D., S. Kyuwa, C. Tam, T. Kakiuchi, A. Matsuzawa, L. T. Williams, and H. Nakano. 1999. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J. Exp. Med. 189:451.
42. Saeki, H., A. M. Moore, M. J. Brown, and S. T. Hwang. 1999. Cutting edge: secondary lymphoid-tissue chemokine (SLC) and CC chemokine receptor 7 (CCR7) participate in the emigration pathway of mature dendritic cells from the skin to regional lymph nodes. J. Immunol. 162:2472.
43. Kellermann, S. A., S. Hudak, E. R. Oldham, Y. J. Liu, and L. M. McEvoy. 1999. The CC chemokine receptor-7 ligands 6Ckine and macrophage inflammatory protein-3β are potent chemoattractants for in vitro-and in vivo-derived dendritic cells. J. Immunol. 162:3859.
44. Sallusto, F., B. Palermo, D. Lenig, M. Miettinen, S. Matikainen, I. Julkunen, R. Forster, R. Burgstahler, M. Lipp, and A. Lanzavecchia. 1999. Distinct patterns and kinetics of chemokine production regulate dendritic cell function. Eur. J. Immunol. 29:1617.
45. Tang, H. L., and J. G. Cyster. 1999. Chemokine up-regulation and activated T cell attraction by maturing dendritic cells. Science 284:819.
46. Rescigno, M., C. Winzler, D. Delia, C. Mutini, M. Lutz, and P. Ricciardi-Castagnoli. 1997. Dendritic cell maturation is required for initiation of the immune response. J. Leukocyte Biol. 61:415.
47. Steinman, R. M., M. Pack, and K. Inaha. 1997. Dendritic cell development and maturation. Adv. Exp. Med. Biol. 417:1.